Contact this trialFirst, we need to learn more about you.
mTOR Inhibitor
Itacitinib + Everolimus for Hodgkin Lymphoma
Recruiting1 awardPhase 1 & 2
Philadelphia, Pennsylvania
This trial will study the safety and effectiveness of itacitinib in combination with everolimus in people with cHL that has relapsed or is resistant to treatment.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service